The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal
 
Status Awaiting development
Decision None selected
Process TA
ID number 3799

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 May 2021 The topic liposomal bupivacaine for treating post-operative pain was scoped by the National Institute for Health and Care Excellence (NICE) as a Technology Appraisal Following the written consultation on the draft remit and scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel (TSOP) in April 2021. The report included advice and recommendations to aid the decision-making process as to whether the topic should continue to be appraised in the NICE work programme. TSOP concluded the topic liposomal bupivacaine for treating post-operative pain was not suitable for a Technology Appraisal since the benefits of this technology cannot be adequately quantified within the Technology Appraisal methods framework. The possibility of an evidence summary will be explored. If you have questions regarding this statement please contact the Scoping Project manager, Michelle Adhemar at scopingta@nice.org.uk
22 January 2021 (10:00) Scoping workshop
25 November 2020 - 23 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual